非霍奇金淋巴瘤患者血清LDH与β2-MG检测及其临床意义

目的探讨非霍奇金淋巴瘤（NHL）患者血清乳酸脱氢酶（LDH）及β2-微球蛋白（β2-MG）水平检测与临床诊断、分期及治疗效果的关系。方法筛选32例初诊为NHL患者为观察组,其中Ⅰ期5例,Ⅱ期7例,Ⅲ期9例,Ⅳ期11例。以35名健康体检者为正常对照组。全部入组对象均采集清晨空腹静脉血检测LDH、β2-MG值。结果 （1）NHL血清LDH及β2-MG水平明显高于对照组（P〈0.01）;（2）Ⅲ＋Ⅳ期患者血清LDH及β2-MG水平明显高于Ⅰ＋Ⅱ期患者（P〈0.01）;（3）化疗2个疗程后,其血清LDH及β2-MG水平较治疗前明显降低（P〈0.01）。结论血清LDH及β2-MG水平检测可作为NHL诊断、分期、疗效评估的参考指标。

The determination of serum LDH and β2-MG in patients with non-Hodgkin’s lymphoma and its clinical significance

Objective To study the relationship between the serum level of LDH,β2-MG and clinical diagnosis,stage and effectiveness of treatment in patients with non-Hodgkin lymphoma（NHL）.Methods The level of serum LDH and β2-MG in 32 patients with NHL（NHL group） and 35 healthy subjects（control group）were detected respectively.Results（1）The level of serum LDH and β2-MG in NHL group were obviously higher than those in the control group（P＆lt;0.01）;（2）The level of serum LDH and β2-MG in Ⅲ＋Ⅳstage were obviously higher than that in Ⅰ＋Ⅱ stage（P＆lt;0.01）;（3） After two cycles of chemotherapy,there was statistical difference between prechemotherapy and postchemotherapy（P＆lt;0.01）.Conclusion The levels of serum LDH and β2-MG can be taked as an reference index for diagnosis,classification,effectiveness of treatment in the patients with NHL.